NASDAQ:CGTX
Cognition Therapeutics Inc.
Cognition Therapeutics Inc. reported net income of −$23.5M in fiscal 2025. The diluted share count rose 83.2%.Summary generated from Cognition Therapeutics Inc.'s SEC filings. Latest annual report filed Mar 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−88.6%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+83.2%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −29 | −44 | −51 | −54 | −48 |
| Net income | −12 | −21 | −26 | −34 | −23 |
| Free cash flow | −4 | −19 | −16 | −28 | n/a |
Recent filings
- 10-QQuarterly report for the period ended Jun 30, 2026
Aug 7, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 8-KOther events
Jun 24, 2026 - 4Insider transaction report
Jun 22, 2026 - 4Insider transaction report
Jun 22, 2026 - 8-KResults of a shareholder vote
Jun 18, 2026 - 8-KRegulation FD disclosure
Jun 4, 2026 - 8-KOther events
May 21, 2026